NWRN.SW

Healthcare Biotechnology

Newron Pharmaceuticals S.p.A.

CHF 7.47

-0.30 -3.86% today Live

Price History

Not enough data

Price chart data
Date	Price
Oct 7, 2026, live at 11:35 AM ET	7.47

Key Stats

Market Cap

152.74M

Avg Volume

65,257

EPS

-CHF 1.35

52W High

CHF 31.85

52W Low

CHF 7.30

Div. Yield

0.0%

Analyst Ratings

Buy

Str Buy

Buy

Hold

Sell

Str Sell

Valuation

Forward P/E

22.52

P/B Ratio

-14.29

P/S Ratio

14.66

EV/EBITDA

-7.37

EV/Revenue

16.01

Margins

Gross Margin 100.0%

Operating Margin (520.5%)

Net Margin (283.6%)

EBITDA Margin (217.1%)

Growth & Returns

Revenue Growth (YoY)

(73.2%)

Return on Assets

(27.8%)

Liquidity & Leverage

Current Ratio

3.15

Quick Ratio

2.89

Total Cash

32.89M

Total Debt

39.04M

About

Newron Pharmaceuticals S.p.A., a biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson's in the European Union, the United Kingdom, the United States, Latin America, Switzerland, and Japan. The company's lead compound includes Evenamide, an add-on therapy for the treatment of Schizophrenia and treatment-resistant schizophrenia, which is in Phase III clinical trial; and Ralfinamide for the treatment of rare neuropathic pain indication. It has a strategic partnership with Zambon and Meiji Seika Pharma Co., Ltd. for the commercialization of safinamide. Newron Pharmaceuticals S.p.A. was founded in 1999 and is headquartered in Bresso, Italy.